









Markets
/
Stocks
/
nasdaq-syre
/

Spyre Therapeutics Inc

SYRE

35.120USD

+2.180+6.62%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.12BMarket Cap

LossP/E TTM



Spyre Therapeutics Inc

35.120

+2.180+6.62%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Spyre Therapeutics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Spyre Therapeutics Inc's fundamentals are relatively weak, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 57 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 56.43.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Spyre Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

57 / 392

Overall Ranking

176 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Spyre Therapeutics Inc Highlights

StrengthsRisks

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in creating inflammatory bowel disease (IBD) and other immune-mediated disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches. Its pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. Its pipeline programs include SPY003, SPY004, SPY130, SPY230, SPY002, SPY001, and SPY120. Its advanced product candidate, SPY001, is a fully human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD. Its co-lead program, SPY002, has nominated two fully human mAb candidates designed to bind to tumor necrosis factor-like ligand 1A (TL1A), both of which are in preclinical development for the treatment of IBD. SPY003 is a preclinical-stage program designed to bind to Interleukin 23 (IL-23) and incorporates half-life extending modifications.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -13.87, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 66.99M shares, decreasing 8.25% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 22.93K shares of this stock.

Analyst Rating

Based on 15 analysts

Strong Buy

Current Rating

56.429

Target Price

+75.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Spyre Therapeutics Inc is 5.19, ranking 378 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.19

Change



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.71

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Spyre Therapeutics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Spyre Therapeutics Inc is 5.85, ranking 360 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -13.87, which is -121.08% below the recent high of 2.92 and 0.00% above the recent low of -13.87.

Score

Industry at a Glance

Previous score

5.85

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 57/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Spyre Therapeutics Inc is 9.20, ranking 9 out of 392 in the Biotechnology & Medical Research industry. The average price target is 49.00, with a high of 70.00 and a low of 21.00.

Score

Industry at a Glance

Previous score

9.20

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 15 analysts

Strong Buy

Current Rating

56.429

Target Price

+75.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Spyre Therapeutics Inc

SYRE

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Spyre Therapeutics Inc is 9.79, ranking 2 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 36.89 and the support level at 31.68, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.13

Change

0.66

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.056

Buy

RSI(14)

60.773

Neutral

STOCH(KDJ)(9,3,3)

74.936

Buy

ATR(14)

1.881

Low Volatility

CCI(14)

162.238

Buy

Williams %R

2.098

Overbought

TRIX(12,20)

0.140

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

33.234

Buy

MA10

33.052

Buy

MA20

32.940

Buy

MA50

32.477

Buy

MA100

26.565

Buy

MA200

21.233

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Spyre Therapeutics Inc is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 86.34%, representing a quarter-over-quarter increase of 1.23%. The largest institutional shareholder is The Vanguard, holding a total of 4.02M shares, representing 5.18% of shares outstanding, with 8.25% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

8.97M

+4.22%

The Vanguard Group, Inc.

Star Investors

3.04M

-0.52%

Fairmount Funds Management LLC

4.02M

RTW Investments L.P.

3.62M

BlackRock Institutional Trust Company, N.A.

3.59M

+0.23%

Deutsch (Peter E)

3.55M

+825.37%

Tang Capital Management, LLC

3.20M

VR Adviser, LLC

2.69M

Braidwell LP

2.58M

Capital International Investors

2.39M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Spyre Therapeutics Inc is 4.84, ranking 68 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 3.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.